Guggenheim initiated coverage of Adaptive Biotechnologies (ADPT) with a Buy rating and $20 price target
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADPT:
- 3 Stocks Flashing Strong Buy Signals on Technical Charts
- Adaptive Biotechnologies: Strategic Shift and Financial Realignment Support Buy Rating
- Adaptive Biotechnologies: Strategic Flexibility and Robust MRD Growth Drive Buy Rating
- Adaptive Biotechnologies down 5% after Genentech pact terminated
- Adaptive Biotechnologies: Strategic Flexibility and Innovation Drive Buy Rating